• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.8200 -0.0185 (-2.21%)
Official Closing Price Updated: 4:10 PM EST, Nov 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,310,471
Open 0.8366
Bid (Size) 0.8200 (1,000)
Ask (Size) 0.8530 (500)
Prev. Close 0.8385
Today's Range 0.8200 - 0.8500
52wk Range 0.7697 - 1.985
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lineage (LCTX) Q3 2026 Earnings Call Transcript ↗
November 13, 2026
Lineage adds a Huntington's program and shifts its cash runway outlook. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call ↗
November 13, 2026
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has acquired privately held NeuroAirmid Therapeutics, adding an experimental Huntington’s disease cell therapy to its clinical pipeline as the company... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 58.7% below 52-week high
0.8200
0.7752W Low 1.9952W High
1 Week 27.1% below 1-week high
0.771W Low 1.121W High

Lineage Cell Therapeutics, Inc. Common Stock (LCTX) traded between $0.77 and $1.99 over the past 52 weeks and last traded at $0.82, 58.7% below its 52-week high. Over the past week it ranged between $0.77 and $1.12.

Past 12 Months
-17.2%
-13.9%
-25.5%
-36.4%
-50.0%
-53.7%
1W -$0.17
1M -$0.13
3M -$0.28
6M -$0.47
YTD -$0.82
1Y -$0.95

LCTX was -53.7% over the past year, -36.4% over six months, -50.0% year to date, -17.2% in the last week.

12 Months vs Market
LCTX
-53.7%
DIA
+6.4%
SPY
+8.5%
QQQ
+8.2%
IWM
+13.2%

Over the past 12 months LCTX returned -53.7% versus DIA (Dow) +6.4%, SPY (S&P 500) +8.5%, QQQ (Nasdaq 100) +8.2% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 0.81× 3-mo avg
Today 1,310,471 3-mo avg 1.6M
1W
4.8M
1M
2.1M
3M
1.6M
6M
1.5M
YTD
1.4M
1Y
1.4M

LCTX most recently traded 1,310,471 shares against a 3-month average daily volume of 1.6M.

More News

Read More
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 12, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances ↗
August 06, 2026
Via Chartmill
Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment ↗
May 12, 2026
Via Chartmill
Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss ↗
March 05, 2026
Via Chartmill
News headline image
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
November 12, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
November 05, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Provides Update on ReSonance® Program for Hearing Loss
October 29, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
September 08, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Lineage Cell Therapeutics Q2 Earnings Call Highlights ↗
August 09, 2026
Via MarketBeat
Topics Earnings
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 06, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
July 30, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan ↗
July 14, 2026
Via MarketBeat
News headline image
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
July 13, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
July 06, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call ↗
July 01, 2026
Via Benzinga
Topics Earnings
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
May 20, 2026
Via FinancialNewsMedia
News headline image
Lineage Cell Therapeutics Q1 Earnings Call Highlights ↗
May 15, 2026
Via MarketBeat
Topics Earnings
News headline image
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
May 05, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
May 04, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Formation of Scientific Advisory Board
April 13, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
March 24, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Lineage Cell Therapeutics, Inc. Common Stock publicly traded?
Yes, Lineage Cell Therapeutics, Inc. Common Stock is publicly traded.
What exchange does Lineage Cell Therapeutics, Inc. Common Stock trade on?
Lineage Cell Therapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock?
The ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock is LCTX on the New York Stock Exchange
What is the current price of Lineage Cell Therapeutics, Inc. Common Stock?
The current price of Lineage Cell Therapeutics, Inc. Common Stock is 0.8200
When was Lineage Cell Therapeutics, Inc. Common Stock last traded?
The last trade of Lineage Cell Therapeutics, Inc. Common Stock was at 11/19/26 04:10 PM ET
What is the market capitalization of Lineage Cell Therapeutics, Inc. Common Stock?
The market capitalization of Lineage Cell Therapeutics, Inc. Common Stock is 143.49M
How many shares of Lineage Cell Therapeutics, Inc. Common Stock are outstanding?
Lineage Cell Therapeutics, Inc. Common Stock has 143M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap